Table of Contents 
Influenza Research and Treatment
Volume 2013, Article ID 286158, 9 pages
http://dx.doi.org/10.1155/2013/286158
Research Article

Comparative Serological Assays for the Study of H5 and H7 Avian Influenza Viruses

Eleonora Molesti,1 Adelaide Milani,2 Calogero Terregino,2 Giovanni Cattoli,2 and Nigel J. Temperton1

1Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Central Avenue, Chatham Maritime, Kent ME4 4TB, UK
2FAO-OIE and National Reference Laboratory for Newcastle Disease and Avian Influenza, Istituto Zooprofilattico delle Venezie, Viale dell’Università 10, 35020 Legnaro, Italy

Received 28 June 2013; Accepted 16 August 2013

Academic Editor: Prasert Auewarakul

Copyright © 2013 Eleonora Molesti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Joannis, L. H. Lombin, P. De Benedictis, G. Cattoli, and I. Capua, “Confirmation of H5N1 avian influenza in Africa,” Veterinary Record, vol. 158, no. 9, pp. 309–310, 2006. View at Google Scholar · View at Scopus
  2. G. Kayali, A. Kandeil, R. El-Shesheny et al., “Do commercial avian influenza H5 vaccines induce cross-reactive antibodies against contemporary H5N1 viruses in Egypt?” Poultry Science, vol. 92, pp. 114–118, 2013. View at Google Scholar
  3. G. Neumann, C. A. Macken, A. I. Karasin, R. A. Fouchier, and Y. Kawaoka, “Egyptian H5N1 influenza viruses-cause for concern?” PLOS Pathogens, vol. 8, Article ID e1002932, 2012. View at Google Scholar
  4. C. Grund, E.-S. M. Abdelwhab, A.-S. Arafa et al., “Highly pathogenic avian influenza virus H5N1 from Egypt escapes vaccine-induced immunity but confers clinical protection against a heterologous clade 2.2.1 Egyptian isolate,” Vaccine, vol. 29, no. 33, pp. 5567–5573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. O. Donis, G. Smith, I. H. Brown et al., “Continuing progress towards a unified nomenclature for the highly pathogenic H5N1 avian influenza viruses: divergence of clade 2·2 viruses,” Influenza and other Respiratory Viruses, vol. 3, no. 2, pp. 59–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. G. J. D. Smith and R. O. Donis, “Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature,” Influenza and other Respiratory Viruses, vol. 6, no. 1, pp. 1–5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. L. Balish, C. T. Davis, M. D. Saad et al., “Antigenic and genetic diversity of highly pathogenic avian influenza a (H5N1) viruses isolated in Egypt,” Avian Diseases, vol. 54, no. 1, pp. 329–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Cattoli, I. Monne, A. Fusaro et al., “Highly pathogenic avian influenza virus subtype H5N1 in Africa: a comprehensive phylogenetic analysis and molecular characterization of isolates,” PLoS ONE, vol. 4, no. 3, Article ID e4842, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Fusaro, T. Joannis, I. Monne et al., “Introduction into Nigeria of a distinct genotype of avian influenza virus (H5N1),” Emerging Infectious Diseases, vol. 15, no. 3, pp. 445–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Capua and S. Marangon, “Control and prevention of avian influenza in an evolving scenario,” Vaccine, vol. 25, no. 30, pp. 5645–5652, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. K. G. Nicholson, A. E. Colegate, A. Podda et al., “Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza,” Lancet, vol. 357, no. 9272, pp. 1937–1943, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Terregino, A. Toffan, F. Cilloni et al., “Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests,” Avian Pathology, vol. 39, no. 3, pp. 215–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C.-W. Lee, D. A. Senne, and D. L. Suarez, “Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus,” Journal of Virology, vol. 78, no. 15, pp. 8372–8381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. E. M. Abdelwhab, C. Grund, M. M. Aly, M. Beer, T. C. Harder, and H. M. Hafez, “Multiple dose vaccination with heterologous H5N2 vaccine: immune response and protection against variant clade 2.2.1 highly pathogenic avian influenza H5N1 in broiler breeder chickens,” Vaccine, vol. 29, no. 37, pp. 6219–6225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Cattoli, A. Milani, N. Temperton et al., “Antigenic drift in H5N1 avian influenza virus in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to those for human influenza virus,” Journal of Virology, vol. 85, no. 17, pp. 8718–8724, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. G. L. Chen and K. Subbarao, “Attacking the flu: neutralizing antibodies may lead to “universal” vaccine,” Nature Medicine, vol. 15, no. 11, pp. 1251–1252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Desvaux, J. M. Garcia, T. D. Nguyen et al., “Evaluation of serological tests for H5N1 avian influenza on field samples from domestic poultry populations in Vietnam: consequences for surveillance,” Veterinary Microbiology, vol. 156, no. 3-4, pp. 277–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Comin, N. Toft, A. Stegeman, D. Klinkenberg, and S. Marangon, “Serological diagnosis of avian influenza in poultry: is the haemagglutination inhibition test really the “gold standard”?” Influenza and Other Respiratory Viruses, vol. 7, pp. 257–264, 2013. View at Google Scholar
  19. S. A. Harper, K. Fukuda, T. M. Uyeki, N. J. Cox, and C. B. Bridges, “Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP),” Morbidity and Mortality Weekly Report, vol. 54, no. 8, pp. 1–40, 2005. View at Google Scholar · View at Scopus
  20. J. M. Katz, W. Lim, C. B. Bridges et al., “Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts,” Journal of Infectious Diseases, vol. 180, no. 6, pp. 1763–1770, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Sui, W. C. Hwang, S. Perez et al., “Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses,” Nature Structural and Molecular Biology, vol. 16, no. 3, pp. 265–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Wang, C. M. Anderson, C. J. de Feo et al., “Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza a strains influenced by a mutation in hemagglutinin subunit 2,” PLoS Pathogens, vol. 7, no. 6, Article ID e1002081, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. T. T. Wang, G. S. Tan, R. Hai et al., “Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins,” PLoS Pathogens, vol. 6, no. 2, Article ID e1000796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Pica, R. Hai, F. Krammer et al., “Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2573–2578, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Steel, A. C. Lowen, T. T. Wang et al., “Influenza virus vaccine based on the conserved hemagglutinin stalk domain,” mBio, vol. 1, no. 1, Article ID e00018-10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Hashem, G. Van Domselaar, C. Li et al., “Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus,” Biochemical and Biophysical Research Communications, vol. 403, no. 2, pp. 247–251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Corti, A. L. Suguitan Jr., D. Pinna et al., “Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine,” Journal of Clinical Investigation, vol. 120, no. 5, pp. 1663–1673, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Alberini, E. Del Tordello, A. Fasolo et al., “Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses,” Vaccine, vol. 27, no. 43, pp. 5998–6003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. N. J. Temperton, K. Hoschler, D. Major et al., “A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies,” Influenza and Other Respiratory Viruses, vol. 1, no. 3, pp. 105–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Molesti, G. Cattoli, F. Ferrara, E. Böttcher-Friebertshäuser, and C. Terregino, “The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses,” Journal of Molecular and Genetic Medicine, vol. 7, pp. 315–320, 2012. View at Google Scholar
  31. E. Wright, N. J. Temperton, D. A. Marston, L. M. McElhinney, A. R. Fooks, and R. A. Weiss, “Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison,” Journal of General Virology, vol. 89, no. 9, pp. 2204–2213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Zufferey, D. Nagy, R. J. Mandel, L. Naldini, and D. Trono, “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,” Nature Biotechnology, vol. 15, no. 9, pp. 871–875, 1997. View at Google Scholar · View at Scopus
  33. L. Naldini, U. Blömer, P. Gallay et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,” Science, vol. 272, no. 5259, pp. 263–267, 1996. View at Google Scholar · View at Scopus
  34. N. J. Temperton, P. K. Chan, G. Simmons et al., “Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes,” Emerging Infectious Diseases, vol. 11, no. 3, pp. 411–416, 2005. View at Google Scholar · View at Scopus
  35. E. Wright, S. McNabb, T. Goddard et al., “A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa,” Vaccine, vol. 27, no. 51, pp. 7178–7186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Demaison, K. Parsley, G. Brouns et al., “High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter,” Human Gene Therapy, vol. 13, no. 7, pp. 803–813, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Niwa, K. Yamamura, and J. Miyazaki, “Efficient selection for high-expression transfectants with a novel eukaryotic vector,” Gene, vol. 108, no. 2, pp. 193–200, 1991. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Besnier, Y. Takeuchi, and G. Towers, “Restriction of lentivirus in monkeys,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11920–11925, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Rowe, R. A. Abernathy, J. Hu-Primmer et al., “Detection of antibody to avian influenza a (H5N1) virus in human serum by using a combination of serologic assays,” Journal of Clinical Microbiology, vol. 37, no. 4, pp. 937–943, 1999. View at Google Scholar · View at Scopus
  40. N. J. Temperton, “The use of retroviral pseudotypes for the measurement of antibody responses to SARS coronavirus,” in Molecular Biology of SARS-Coronavirus, p. 9, Springer, Berlin, Germany, 2010. View at Google Scholar
  41. J.-K. Kim, G. Kayali, D. Walker et al., “Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 24, pp. 11044–11049, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Capua and D. J. Alexander, “Animal and human health implications of avian influenza infections,” Bioscience Reports, vol. 27, no. 6, pp. 359–372, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Banks, E. S. Speidel, E. Moore et al., “Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy,” Archives of Virology, vol. 146, no. 5, pp. 963–973, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Banks and L. Plowright, “Additional glycosylation at the receptor binding site of the hemagglutinin (HA) for H5 and H7 viruses may be an adaptation to poultry hosts, but does it influence pathogenicity?” Avian Diseases, vol. 47, pp. 942–950, 2003. View at Google Scholar · View at Scopus
  45. R. G. Webster, “Influenza virus: transmission between species and relevance to emergence of the next human pandemic,” Archives of Virology, vol. 1997, no. 13, pp. 105–113, 1997. View at Google Scholar · View at Scopus
  46. C. J. Russell and R. G. Webster, “The genesis of a pandemic influenza virus,” Cell, vol. 123, no. 3, pp. 368–371, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Horimoto and Y. Kawaoka, “Pandemic threat posed by avian influenza A viruses,” Clinical Microbiology Reviews, vol. 14, no. 1, pp. 129–149, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. M. T. Osterholm, “Preparing for the next pandemic,” New England Journal of Medicine, vol. 352, no. 18, pp. 1839–1842, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Capua and D. J. Alexander, “Avian influenza vaccines and vaccination in birds,” Vaccine, vol. 26, no. 4, supplement, pp. D70–D73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Anderson, I. Capua, G. Dauphin et al., “FAO-OIE-WHO joint technical consultation on avian influenza at the human-animal interface,” Influenza and Other Respiratory Viruses, vol. 4, pp. 1–29, 2010. View at Google Scholar · View at Scopus
  51. F. Ferrara, E. Molesti, E. Böttcher-Friebertshäuser et al., “The human transmembrane protease serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes,” Journal of Molecular and Genetic Medicine, vol. 7, pp. 309–314, 2012. View at Google Scholar
  52. G. L. Ada and P. D. Jones, “The immune response to influenza infection,” Current Topics in Microbiology and Immunology, vol. 128, pp. 1–54, 1986. View at Google Scholar · View at Scopus
  53. H. Ding, C. Tsai, F. Zhou, P. Buchy, V. Deubel, and P. Zhou, “Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus,” PLoS ONE, vol. 6, no. 3, Article ID e17821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. G. M. Vodeiko and J. P. Weir, “Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza,” Influenza and other Respiratory Viruses, vol. 6, no. 3, pp. 176–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. C.-W. Lee, D. A. Senne, and D. L. Suarez, “Development and application of reference antisera against 15 hemagglutinin subtypes of influenza virus by DNA vaccination of chickens,” Clinical and Vaccine Immunology, vol. 13, no. 3, pp. 395–402, 2006. View at Publisher · View at Google Scholar · View at Scopus